6533b820fe1ef96bd127a517

RESEARCH PRODUCT

Immunogenic hotspots in the spacer domain of ADAMTS13 in immune‐mediated thrombotic thrombocytopenic purpura

Heidi RossmannPaul CoppoBérangère S. JolyElien RooseAndres MännikAgnès VeyradierTanja FalterJan VoorbergEdwige TellierLeydi Carolina Velásquez PereiraGilles KaplanskiBernhard LämmleBernhard LämmleBernhard LämmleHendrik B. FeysMarienn RétiSimon F. De MeyerNuno A. G. GraçaKadri KangroCharis Von AuerKaren VanhoorelbekeGyörgy SinkovitsZoltán Prohászka

subject

autoantibodiesADAMTS13 Protein030204 cardiovascular system & hematologyEpitope03 medical and health sciencesEpitopes0302 clinical medicineVon Willebrand factorimmunophenotypinghemic and lymphatic diseasesHumansthrombotic thrombocytopenic purpurachemistry.chemical_classificationbiologyPurpura Thrombotic ThrombocytopenicAutoantibodyHematologyMolecular biologyADAMTS13ADAMTS133. Good healthAmino acidepitope mappingEpitope mappingchemistryPolyclonal antibodiesImmunoglobulin Gbiology.proteinDNA IntergenicAntibody[SDV.MHEP]Life Sciences [q-bio]/Human health and pathology

description

International audience; Background Immune-mediated thrombotic thrombocytopenic purpura (iTTP) is caused by anti-ADAMTS13 autoantibodies inducing a severe deficiency of ADAMTS13. Epitope mapping studies on samples obtained during acute iTTP episodes have shown that the iTTP immune response is polyclonal, with almost all patients having autoantibodies targeting the spacer domain of ADAMTS13.Objectives To identify the immunogenic hotspots in the spacer domain of ADAMTS13.Patients/methods A library of 11 full-length ADAMTS13 spacer hybrids was created in which amino acid regions of the spacer domain of ADAMTS13 were exchanged by the corresponding region of the spacer domain of ADAMTS1. Next, the full-length ADAMTS13 spacer hybrids were used in enzyme-linked immunosorbent assay to epitope map anti-spacer autoantibodies in 138 samples from acute and remission iTTP patients.Results Sixteen different anti-spacer autoantibody profiles were identified with a similar distribution in acute and remission patients. There was no association between the anti-spacer autoantibody profiles and disease severity. Almost all iTTP samples contained anti-spacer autoantibodies against the following three regions: amino acid residues 588-592, 602-610, and 657-666 (hybrids E, G, and M). Between 31% and 57% of the samples had anti-spacer autoantibodies against amino acid regions 572-579, 629-638, 667-676 (hybrids C, J, and N). In contrast, none of the samples had anti-spacer autoantibodies against amino acid regions 556-563, 564-571, 649-656, and 677-685 (hybrids A, B, L, and O).Conclusion We identified three hotspot regions (amino acid regions 588-592, 602-610, and 657-666) in the spacer domain of ADAMTS13 that are targeted by anti-spacer autoantibodies found in a large cohort of iTTP patients.

10.1111/jth.15170https://hal.inrae.fr/hal-03144317